Jacobs Levy Equity Management’s Pyxis Oncology PYXS Stock Holding History

Jacobs Levy Equity Management’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.29M	Sell	428,606 -32,391	-7%	-$61.9K	﹤0.01%	674
2026 Q1	$673K	Buy	+460,997	New	+$695K	﹤0.01%	775
2025 Q4	–	Sell	-60,333	Closed	-$134K	–	1038
2025 Q3	$134K	Buy	+60,333	New	+$86.9K	﹤0.01%	933
2025 Q1	–	Sell	-601,940	Closed	-$939K	–	1175
2024 Q4	$939K	Buy	601,940 +219,100	+57%	+$632K	﹤0.01%	723
2024 Q3	$1.41M	Buy	+382,840	New	+$1.34M	0.01%	668

Other funds holding PYXS

GGI

GordonMD Global Investments Beverely Hills, California $207M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's PYXS Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Pyxis Oncology (PYXS) stake by 7% in Q2 2026, selling an estimated $61.9K and leaving 428,606 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #674.

Jacobs Levy Equity Management first reported a position in PYXS in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.41M in Q3 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

Jacobs Levy Equity Management held 428,606 shares of Pyxis Oncology worth $1.29M as of Q2 2026.
Jacobs Levy Equity Management sold 32,391 Pyxis Oncology shares in Q2 2026, an estimated $61.9K.
Pyxis Oncology made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #674 holding.
Jacobs Levy Equity Management first reported a position in Pyxis Oncology in Q3 2024 and has held it in 5 quarters since.
Jacobs Levy Equity Management's Pyxis Oncology position peaked at $1.41M in Q3 2024.
76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.